Bristol-Myers Squibb Company (OTCMKTS:BMYMP) Files An 8-K Other Events

Bristol-Myers Squibb Company (OTCMKTS:BMYMP) Files An 8-K Other Events

Story continues below

Item 8.01. Other Events.

On February 22, 2017, Bristol-Myers Squibb Company (the Company)
agreed to sell $750,000,000 aggregate principal amount of its
1.600% notes due 2019 and $750,000,000 aggregate principal amount
of its 3.250% notes due 2027 (collectively, the Notes), to the
Underwriting Agreement, dated February 22, 2017 (the Underwriting
Agreement), among the Company and Goldman, Sachs Co., Morgan
Stanley Co. LLC and Merrill Lynch, Pierce, Fenner Smith
Incorporated, as representatives of the several underwriters
listed on Schedule II of the Underwriting Agreement.
The sale of the Notes closed on February 27, 2017. The Notes were
issued to that certain Indenture, dated as of June 1, 1993 (the
Indenture), between the Company and The Bank of New York Mellon,
as trustee (the Trustee), as supplemented by the Ninth
Supplemental Indenture, dated as of February 27, 2017, between
the Company and the Trustee (the Ninth Supplemental Indenture).
The offer and sale of the Notes has been registered under the
Securities Act of 1933, as amended, by a Registration Statement
on Form S-3 (No. 333-206991).
The Underwriting Agreement is filed as Exhibit 1.1 to this
Current Report on Form 8-K. The Ninth Supplemental Indenture is
filed as Exhibit 4.1 to this Current Report on Form 8-K. The
forms of Notes are filed as Exhibits 4.2 and 4.3, respectively,
to this Current Report on Form 8-K. In connection with the
issuance of the Notes, the opinion of Covington Burling LLP with
respect to the validity of the Notes is being filed as Exhibit
5.1 to this Current Report on Form 8-K.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits.
Exhibit No.
Description
1.1
Underwriting Agreement, dated February 22, 2017, relating
to the $750,000,000 1.600% notes due 2019 and $750,000,000
3.250% notes due 2027.
4.1
Ninth Supplemental Indenture, dated as of February 27,
2017, between Bristol-Myers Squibb Company and The Bank of
New York Mellon, as Trustee, to the Indenture dated as of
June 1, 1993.
4.2
Form of $750,000,000 1.600% Notes due 2019 (included as
Exhibit A to Exhibit 4.1).
4.3
Form of $750,000,000 3.250% Notes due 2027 (included as
Exhibit B to Exhibit 4.1).
5.1
Opinion of Covington Burling LLP relating to the Notes.
23.1
Consent of Covington Burling LLP (set forth in Exhibit
5.1).


About Bristol-Myers Squibb Company (OTCMKTS:BMYMP)

Bristol-Myers Squibb Company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. The Company’s pharmaceutical products include chemically synthesized drugs, or small molecules, and products produced from biological processes called biologics. Small molecule drugs are administered orally in the form of a pill or tablet. Biologics are administered to patients through injections or by infusion. It offers products for a range of therapeutic classes, which include virology, including human immunodeficiency virus (HIV) infection; oncology; immunoscience; cardiovascular, and neuroscience. Its late-stage investigational compounds that are in Phase III clinical trials include Beclabuvir, BMS-663068 and Prostvac.

Bristol-Myers Squibb Company (OTCMKTS:BMYMP) Recent Trading Information

Bristol-Myers Squibb Company (OTCMKTS:BMYMP) closed its last trading session 00.00 at 1,010.69 with shares trading hands.

An ad to help with our costs